ME00935B - Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću - Google Patents

Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću

Info

Publication number
ME00935B
ME00935B MEP-2009-299A MEP29909A ME00935B ME 00935 B ME00935 B ME 00935B ME P29909 A MEP29909 A ME P29909A ME 00935 B ME00935 B ME 00935B
Authority
ME
Montenegro
Prior art keywords
cyclopropylmethoxy
carboxamide
dichloro
methoxy
parkinson
Prior art date
Application number
MEP-2009-299A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ME00935B publication Critical patent/ME00935B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MEP-2009-299A 2007-04-19 2008-04-16 Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću ME00935B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
ME00935B true ME00935B (me) 2012-06-20

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-299A ME00935B (me) 2007-04-19 2008-04-16 Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955808A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
AU2004220456B2 (en) * 2003-03-12 2010-10-14 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
CA2684174C (fr) 2014-02-25
FR2915100A1 (fr) 2008-10-24
PT2146714E (pt) 2011-09-02
JO2678B1 (en) 2013-03-03
CA2684174A1 (fr) 2008-12-04
ZA200907251B (en) 2011-04-28
ATE513548T1 (de) 2011-07-15
EP2146714B1 (fr) 2011-06-22
CN101663035B (zh) 2012-06-20
US20100130554A1 (en) 2010-05-27
HK1141725A1 (en) 2010-11-19
HRP20110666T1 (hr) 2011-10-31
KR20150004885A (ko) 2015-01-13
KR20090130059A (ko) 2009-12-17
UY31035A1 (es) 2008-11-28
BRPI0810444A2 (pt) 2016-05-31
CN101663035A (zh) 2010-03-03
DK2146714T3 (da) 2011-10-10
SI2146714T1 (sl) 2011-10-28
ES2367408T3 (es) 2011-11-03
EA200970970A1 (ru) 2010-02-26
JP5386478B2 (ja) 2014-01-15
CL2008001136A1 (es) 2009-01-16
FR2915100B1 (fr) 2009-06-05
MY148092A (en) 2013-02-28
CY1111840T1 (el) 2015-10-07
TWI439269B (zh) 2014-06-01
AR066108A1 (es) 2009-07-22
AU2008257322A1 (en) 2008-12-04
KR101503942B1 (ko) 2015-03-18
TW200911247A (en) 2009-03-16
IL201448A (en) 2014-08-31
WO2008145841A1 (fr) 2008-12-04
MX2009011284A (es) 2009-11-02
RS51869B (sr) 2012-02-29
EA019194B1 (ru) 2014-01-30
PA8776801A1 (es) 2008-11-19
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
PL2146714T3 (pl) 2011-10-31
IL201448A0 (en) 2010-05-31
EP2146714A1 (fr) 2010-01-27
NZ580482A (en) 2011-10-28
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
DK2150530T3 (da) Substituerede sulfonamid-derivater
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
UY30183A1 (es) Derivados de quinolina
HRP20050710A2 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
WO2012048129A3 (en) Inhibitors of polo-like kinase
CY1109460T1 (el) Υποκατεστημενες ενωσεις 5,6,7,8-τετραϋδρο-ιμιδαζο[1,2-α]-πυριδιν-2-υλαμινης και η χρησιμοποιηση τους για την παρασκευη φαρμακων
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
TN2015000356A1 (en) Bicyclic compounds
ME00935B (me) Upotreba 4-ciklopropilmetoksi-&lt;i&gt;n&lt;/i&gt;-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
HRP20110459T1 (hr) Upotreba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju ozljeda kralježnične moždine
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
HRP20120130T1 (hr) Upotreba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksido-4-piridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju ozljeda lubanje
HRP20130983T1 (hr) Derivati arilciklopropilacetamida, korisni kao aktivatori glukokinaze
WO2015036898A3 (en) Novel salts of crizotinib and their preparation